Bright Green Eyes Importing Controlled Substances Legally
Published Date: 12/19/2025
Notice
Summary
Bright Green Corporation wants to become an official importer of certain controlled substances like raw opium and poppy straw. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 20, 2026. This move could affect how these substances enter the U.S. and might impact businesses dealing with them.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
New Importer Application for Raw Opiates
Bright Green Corporation applied on July 11, 2025 to be a registered importer of Schedule II raw opium (drug code 9600), poppy straw (9650), and poppy straw concentrate (9670). The application seeks authorization to import those substances in bulk form.
Stakeholders Can Comment or Request Hearing
Registered bulk manufacturers of the affected substances and applicants may submit electronic comments or objections and may file written requests for a hearing on this application on or before January 20, 2026. Comments must be submitted through https://www.regulations.gov.
Import Authorization Limited to Bulk Materials
If registered, Bright Green's authorization would be limited to importing the listed substances in bulk for domestic manufacturing (growing) to supply other DEA-registered manufacturers. The registration would not authorize importing FDA-approved or non-approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-23467, Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals wants to make a lot of methylphenidate, a controlled drug used to treat conditions like ADHD. They’ve applied to get official permission to do this, and anyone who has concerns can speak up by February 17, 2026. This move affects drug makers and buyers and could impact the supply of this medicine.
Next: 2025-23469, Importer of Controlled Substances Application: Aveva Drug Delivery Systems, Inc.
Aveva Drug Delivery Systems, Inc. wants to become an official importer of a controlled substance called Thebaine, which is a Schedule II drug. This means they’ll be allowed to bring this drug into the U.S. for medical or research use. People who make or use these drugs can share their thoughts or ask for a hearing by January 20, 2026.